- Home
- NGNE vs FACT Comparison
NGNE vs FACT Comparison
Compare NGNE & FACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- FACT
- Stock Information
- Founded
- NGNE 2003
- FACT 2024
- Country
- NGNE United States
- FACT United States
- Employees
- NGNE N/A
- FACT N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- FACT
- Sector
- NGNE Health Care
- FACT
- Exchange
- NGNE Nasdaq
- FACT NYSE
- Market Cap
- NGNE 251.9M
- FACT 245.6M
- IPO Year
- NGNE N/A
- FACT 2024
- Fundamental
- Price
- NGNE $21.83
- FACT $10.23
- Analyst Decision
- NGNE Buy
- FACT
- Analyst Count
- NGNE 6
- FACT 0
- Target Price
- NGNE $39.83
- FACT N/A
- AVG Volume (30 Days)
- NGNE 224.0K
- FACT 81.8K
- Earning Date
- NGNE 05-09-2025
- FACT 01-01-0001
- Dividend Yield
- NGNE N/A
- FACT N/A
- EPS Growth
- NGNE N/A
- FACT N/A
- EPS
- NGNE N/A
- FACT N/A
- Revenue
- NGNE $925,000.00
- FACT N/A
- Revenue This Year
- NGNE N/A
- FACT N/A
- Revenue Next Year
- NGNE N/A
- FACT N/A
- P/E Ratio
- NGNE N/A
- FACT N/A
- Revenue Growth
- NGNE N/A
- FACT N/A
- 52 Week Low
- NGNE $6.88
- FACT $9.85
- 52 Week High
- NGNE $74.49
- FACT $10.32
- Technical
- Relative Strength Index (RSI)
- NGNE 62.53
- FACT N/A
- Support Level
- NGNE $16.62
- FACT N/A
- Resistance Level
- NGNE $18.90
- FACT N/A
- Average True Range (ATR)
- NGNE 2.06
- FACT 0.00
- MACD
- NGNE 0.38
- FACT 0.00
- Stochastic Oscillator
- NGNE 60.81
- FACT 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About FACT FACT II ACQUISITION CORP
FACT II Acquisition Corp is a blank check company.